Advanced search
Publication Cover
Oncology Issues Volume 26, 2011 - Issue 5
Journal homepage
2
Views
0
CrossRef citations to date
0
Altmetric
Nurses Physician Collaboration

Implementing a Community-Based Breast Cancer Risk-Assessment Model

Birjis AkhundView further author information
, MD,
Gail ProbstView further author information
, RN, MS, ANP, AOCN, NE-BC,
John WagnerView further author information
, MD, FACOG &
Rosemary ThideView further author information
, RNC, BSN
Pages 36-42 | Published online: 01 Aug 2017

References

  • National Cancer Institute. Breast Cancer. Available online at: http://www.cancer.gov/cancertopics/types/breast. Last accessed May 18, 2011.
  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.
  • Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741.
  • Kaplan CP, Haas JS, Pérez-Stable EJ, Des Jarlais G, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41(1):7–15.
  • Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006;166(20):2260–2265.
  • Gail MH, Costantino JP, Bryant J, Croyle R, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829–1846.
  • Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, et al. Women's decisions regarding tamoxifen for breast cancer prevention: Responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119(3):613–620.
  • Tjia J, Micco E, Armstrong K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat. 2008;108(3):435–53.
  • Chlebowski RT, Col N, Winer EP, Collyar DE, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20(15):3328–3343.
  • Melnikow J, Paterniti D, Azari R, Kuenneth C, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103(10):1996–2005.
  • National Cancer Institute. Breast Cancer Risk Assessment Tool. Available online at: http://www.cancer.gov/bcrisktool/. Last accessed on May 18, 2011.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.